Systemic Juvenile Idiopathic Arthritis Clinical Trial
Official title:
A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306 (NCT02296424) or CACZ885N2301 (NCT02059291) until a decision regarding reimbursement in France is effective for canakinumab (Ilaris®) in these indications.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00891046 -
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
|
Phase 3 | |
| Completed |
NCT01304420 -
Ultrasonography in Juvenile Idiopathic Arthritis
|
Phase 0 | |
| Completed |
NCT01803321 -
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1 | |
| Completed |
NCT00144664 -
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
Phase 3 | |
| Completed |
NCT02396212 -
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
|
Phase 3 | |
| Completed |
NCT00144599 -
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Terminated |
NCT00886769 -
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
| Completed |
NCT00144612 -
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Withdrawn |
NCT01676948 -
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
| Recruiting |
NCT04088396 -
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Recruiting |
NCT05027373 -
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
|
Phase 1 |